Merck stock in focus after CDC rewrites childhood vaccine schedule, puts Gardasil dosing under a microscope
Merck shares rose 1.3% to $108.87 Tuesday after U.S. health officials revised the childhood vaccine schedule and backed a one-dose HPV regimen. Gardasil, Merck’s HPV vaccine, brought in $2.4 billion U.S. sales in 2024. Investors await Merck’s Jan. 12 JPMorgan conference appearance and Feb. 3 earnings call.